Targeted therapy in ophthalmic oncology: The current status.
| Autor: | Sen M; Ocular Oncology Service, Raghunath Netralaya, Mumbai, India., Demirci H; Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, MI, USA., Honavar SG; Ocular Oncology Service, Centre for Sight Eye Hospital, Hyderabad, India. Electronic address: santosh.honavar@gmail.com. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) [Asia Pac J Ophthalmol (Phila)] 2024 Mar-Apr; Vol. 13 (2), pp. 100062. Date of Electronic Publication: 2024 Apr 19. |
| DOI: | 10.1016/j.apjo.2024.100062 |
| Abstrakt: | There have been rapid advancements in the field of ocular oncology for the diagnosis and management of intraocular, adnexal, and orbital tumors. Targeted therapy is in the forefront of medical research in all fields including ocular oncology. Targeted therapy include drugs that target specific genetic mutations, pathways or proteins involved in the development of cancer. In contrast to traditionally used chemotherapy, drugs used in targeted therapy are highly specific for tumor cells and preserve the function of normal cells. This review aims to familiarize ophthalmologists with the drugs that are currently approved or undergoing clinical trials for use in ocular oncology. Targeted therapy is particularly useful for locally advanced or metastatic tumors, including but not limited to eyelid and periocular basal cell carcinoma, periocular cutaneous and conjunctival squamous cell carcinoma, ocular adnexal lymphoma, conjunctival melanoma, and uveal melanoma. The results are promising with improved survival outcomes and better tolerability than chemotherapeutic drugs. (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|